US20010012637A1 - Device for the testing of body fluid samples - Google Patents
Device for the testing of body fluid samples Download PDFInfo
- Publication number
- US20010012637A1 US20010012637A1 US09/770,312 US77031201A US2001012637A1 US 20010012637 A1 US20010012637 A1 US 20010012637A1 US 77031201 A US77031201 A US 77031201A US 2001012637 A1 US2001012637 A1 US 2001012637A1
- Authority
- US
- United States
- Prior art keywords
- test
- drug
- container
- card
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000012360 testing method Methods 0.000 title claims abstract description 265
- 210000001124 body fluid Anatomy 0.000 title description 4
- 239000010839 body fluid Substances 0.000 title description 4
- 239000003814 drug Substances 0.000 claims abstract description 72
- 229940079593 drug Drugs 0.000 claims abstract description 71
- 239000012530 fluid Substances 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims abstract description 28
- 230000008569 process Effects 0.000 claims abstract description 22
- 238000003018 immunoassay Methods 0.000 claims abstract description 19
- 238000003255 drug test Methods 0.000 claims abstract description 17
- 230000000007 visual effect Effects 0.000 claims abstract description 14
- 206010013654 Drug abuse Diseases 0.000 claims abstract description 13
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 13
- 238000003677 abuse test Methods 0.000 claims abstract description 12
- 239000012491 analyte Substances 0.000 claims description 7
- 239000012780 transparent material Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 abstract description 12
- 230000004048 modification Effects 0.000 abstract description 12
- 238000003908 quality control method Methods 0.000 abstract description 6
- 239000000523 sample Substances 0.000 description 45
- 210000002700 urine Anatomy 0.000 description 30
- 239000000463 material Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000007877 drug screening Methods 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010042618 Surgical procedure repeated Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012815 thermoplastic material Substances 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A61B10/007—Devices for taking samples of body liquids for taking urine samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
- G01N33/525—Multi-layer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0096—Casings for storing test samples
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B2010/0003—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements including means for analysis by an unskilled person
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B2010/0009—Testing for drug or alcohol abuse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N2001/002—Devices for supplying or distributing samples to an analysing apparatus
- G01N2001/005—Packages for mailing or similar transport of samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N2001/002—Devices for supplying or distributing samples to an analysing apparatus
- G01N2001/007—Devices specially adapted for forensic samples, e.g. tamper-proofing, sample tracking
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/97—Test strip or test slide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/973—Simultaneous determination of more than one analyte
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/815—Test for named compound or class of compounds
- Y10S436/816—Alkaloids, amphetamines, and barbiturates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/901—Drugs of abuse, e.g. narcotics, amphetamine
Definitions
- the present invention relates to a test kit for the collection and testing of urine samples for drugs of abuse and subsequent shipment of the sample, more particularly, to such a test kit for low volumes of urine samples and having a transparent envelope-type container and a test card for indicating visually the presence of particular drugs of abuse.
- the containers incorporated the structure by means of which reagent strips were mounted in a test compartment of the container and which structure also enabled the fluid sample to flow into the test compartment into contact with the reagent strips.
- Such a mounting of the reagent strips further resulted in complicating the structure of the container since it was also necessary that provision be made to view the reagent strips from outside of the container. This was generally achieved by providing a transparent window or some other mounting of the reagent strips so that they are visible to testing personnel.
- test card having a plurality of immunoassay test strips thereon with each strip being responsive to a particular drug of abuse and having a visual endpoint to indicate the presence or absence of a particular drug.
- the drug abuse test device may comprise a flat envelope or bag transparent container for retaining a urine sample to be tested.
- the open top of the container is of such a size to accommodate a test card which has a plurality of immunoassay test strips mounted thereon in parallel on one or both sides and each test strip is responsive to a particular drug of abuse.
- the test card is insertable through the open top or end so as to have one end immersed in the urine sample to a predetermined depth whereby the visual results of each test strip can be seen through the transparent or translucent wall of the container without removing the test card from the container so as to indicate the presence or absence of a particular drug of abuse in the urine sample. If the sample should test “positive” to indicate the presence of a drug in the urine, it is then necessary to send the sample to a certified laboratory for confirmatory testing.
- the test kit includes a drug abuse test device for collecting and testing a urine sample.
- This test device comprises a flat envelope or bag preferably having a transparent wall and having an open top or end in the shape of a slit therein to receive a test card.
- This new test kit would thus test as little as 2.0 ml. of urine or any other fluid sample as compared with the usual 30-48 ml. such as when a test cup is used.
- This test kit incorporates a particular structure of a container rather than the usual test cup. This ability to test lower volumes is ideal for use in hospital and clinical settings as well for compliance with laboratory certification and quality control requirements.
- the test kit also includes a test card for drugs of abuse which may comprise a thin flat member having the size and shape of a business card.
- a plurality of immunoassay test strips are fastened side by side in parallel on one side of the test card within the outline of the card. Each test strip is reactive to provide a visual indication in response to a particular drug of abuse.
- This test card thus provides for the simultaneous detection of multiple analytes.
- FIG. 1 is a perspective view of the drug abuse test kit according to the present invention generally showing the container, the test card partially inserted to the testing position in the container through a slit in the cover;
- FIG. 2 is an exploded perspective view of the container according to the present invention for collecting and testing a fluid sample and generally showing the container, a cover having a slit covered with a removable adhesive seal and a second solid closure cap;
- FIG. 3 is a plan view of the test side of a test card according to the present invention.
- FIG. 4 is a plan view of the reverse side of the test card shown in FIG. 3;
- FIG. 5 is an end elevational view of the test card shown in FIG. 3;
- FIG. 6 is a sectional view taken along the lines VI-VI of FIG. 3 but showing a modification wherein the test strips are flush with the top surface of the test card;
- FIG. 7 is a plan view of the opened two piece test card before it is folded over to form the test card shown in FIGS. 3 - 6 ;
- FIG. 8 is a plan view of another modification of the test card
- FIG. 9 is a sectional view taken along the lines IX-IX of FIG. 8.
- FIG. 10 is a plan view of the test side of a further modification of the test card
- FIG. 11 is a plan view of the center ply of the test card of FIG. 10 and showing a test strip in a slot thereof;
- FIG. 12 is a plan view of the reverse side of the test card of FIG. 10;
- FIG. 13 is a sectional view taken along the lines XIII-XIII of FIG. 10.
- FIG. 14 is a plan view of a flat polybag or envelope used in the low volume test
- FIG. 15 is a side elevational view of the envelope or bag shown in FIG. 14;
- FIG. 16 is a plan view of a polybag according to FIG. 14 with a drug test card partially inserted therein;
- FIG. 17 is a view similar to that of FIG. 16 but shows a drug test card inserted within the polybag in the testing position;
- FIG. 18 is a perspective view of a drug test card in an inclined position for a low volume test utilizing a pipette to dispense the sample to be tested directly onto the test card.
- a drug abuse test kit according to the present invention is indicated generally at 10 and comprises a cup-like transparent test container or cup 11 having a cylindrical side wall 12 , a closed bottom 13 and an open top 14 .
- the cylindrical wall 12 may have a slight taper or be straight.
- the open end 14 of the test cup 11 is provided with external threads 21 upon which is seated an outer closure cover or cap 22 provided with corresponding internal threads which are not shown in the drawing.
- the cover 22 has a circular top surface 23 from the periphery of which depends a cylindrical wall 24 on the inner surface of which there are provided internal threads.
- the cover surface 23 has a diametrical slit 19 therein shaped to accommodate a test card as will be presently described.
- a temperature strip 16 is mounted on the bottom side wall of the test cup so as to be responsive to the temperature of the test sample within a test cup.
- the cup container is essentially a specimen cup as commonly used in medicine and has a wall of material normally impervious to fluid specimens contained therein.
- the container may be formed or molded from any suitable material, such as a thermal plastic. It is preferred that the container is transparent since this enables the results from the test card to be read without removing the test card from the cup. But a transparent wall is not necessary and the wall may be translucent or even opaque. If an opaque material is used, it is preferred that the material be such that a test strip would be visible and read when the test card is close to or in contact with a wall of the container. Further, while the cup shown is cylindrical, it is to be understood that other shapes could be used.
- test card 25 which will indicate the presence or absence of any one of 5 different drugs of abuse is shown in FIG. 1 inserted within the slit 19 in the closure cap 22 and in further detail in FIGS. 3 - 6 .
- the test card is of the multiple drug type in that test strips for five different drugs of abuse are mounted on the test card.
- the test strips 26 - 30 are spaced apart in parallel on a test side 31 of the test card. These test strips indicate the presence or absence of the following specific drugs of abuse: PCP, cocaine, amphetamines (AMP), marijuana (THC) and opiates.
- Test strips 26 - 30 may be of the type as made by Bionike of South San Francisco, California, Phamatech of San Diego, Calif.
- test strips are characterized as immunoassay strips and employ colloidal gold chemistry.
- Each test strip is submerged up to a maximum line indicated at 32 and the results of the test are read in a test area indicated at 33 .
- a blue line in the test area indicates positive or the presence of the particular drug in the test sample.
- the test strips may be completely recessed as shown in FIG. 6 or partially recessed in the slots in the card so that portions of the test strip may project above the test surface 31 of the card as shown in FIG. 5. If the test strips are completely recessed, then the strips would be flush with the top surface of the top ply as shown in FIG. 6.
- the test card may be formed of two plys 34 and 35 as may be seen in FIG. 7 and these plys in turn are formed from a single strip having a bend or fold 36 .
- the ply 35 is formed with a plurality of die cut slots 37 which are shaped and sized to receive each of the test strips.
- the two portions 34 and 35 are folded over at end 36 and are adhered together.
- the test strips are then placed into the slots as shown in FIG. 6 and each of the test strips is adhered to the surface of the first portion 34 upon which the second portion 35 has been folded. In this modification the test strips are flush with the test surface 31 .
- test card of two separate or individual plys 34 and 35 which are then adhered together and the strips are fixed in the slots as described above.
- a person being tested In order to conduct a drug abuse test utilizing the test card according to the present invention a person being tested must first provide a urine specimen into the transparent test cup 11 .
- the quantity of specimen provided must be such as to permit insertion of the test card up to about the maximum line indicated at 32 . It is also possible to provide fill lines on the wall surface of the test container. Usually, 30-48 ml. of specimen is sufficient.
- test cup with a sufficient quantity of test specimen therein is then closed by threading the cap 22 on the top of the test cup.
- the cap 22 is provided with a readily removable adhesive sealing strip 18 which is placed over the slit 19 .
- the protective strip 18 is removed and the multiple drug test card 25 inserted into the slit so that the bottom of the test card rests upon the bottom of the test cup. 30-48 ml. of specimen will ensure that the specimen contacts the sample receiving portions of all of the test strips.
- the test card then remains in place for at least three minutes. results of the test can be read on each individual test strip through the transparent wall of the container.
- the results of the test are positive, it is preferable to send the specimen to a certified laboratory for a confirmatory analysis by more specific methods of testing such as gas chromatography or mass spectrometry.
- the closure 22 is removed and the solid cover 15 is threaded down tightly upon the open end of the container.
- test card 44 A modification of the test card is shown at 44 in FIG. 8.
- the test card 44 comprises a central ply 45 of styrene which has a thickness of 1.25 mm. corresponding to or slightly greater than the thickness of the test strips and slots are provided in the center ply to receive the test strips.
- the top and bottom faces of the central ply 45 are covered by a bottom ply 46 and a top ply 47 which may be made from a single piece of material double scored at 48 and 49 so as to wrap around the central ply 45 in the manner as shown in FIG. 10.
- the top and bottom plys may be of a thin vinyl sheet or cardboard coated with plastic.
- the top ply 47 is provided with a plurality of test windows 50 through which the test results as indicated by the test strips can be seen.
- sample openings 51 At the lower end of the card are provided sample openings 51 through which the liquid test specimen is able to contact the absorbent or sample portions of the test strips.
- FIGS. 10 - 13 there is shown a modification of the test card 44 in which the card is made of three separate plys which are then laminated.
- the bottom and top plys 46 and 47 are made of a thin vinyl sheet having a thickness of 0.33 mm.
- the center ply 45 is made of styrene having a thickness of about 1.25 mm.
- the top ply 47 similarly has the test openings or windows 50 and the sample openings 51 and the bottom ply 46 is solid as shown.
- the central ply 45 is provided with a plurality of longitudinally extending slots 52 and a test strip 53 is seated in each of these slots as shown.
- the test strip generally has a length less than that of the slot 52 .
- only a single test strip for THC (marijuana) is shown. While this embodiment of the test card has provision for five test strips, it is to be understood that the card can be made in the same manner with less than five strips and even a single strip if so desired. In such a modification, the windows 50 and 51 for the omitted strips are usually solid.
- FIG. 14 a clear recloseable bag or envelope of polyethylene which is used in the testing of low volumes of fluid samples for drugs of abuse.
- the bag 54 is a transparent flat bag or envelope having a rectangular configuration and a top 55 which is open and a bottom 56 .
- the top 55 is provided with a zip-lock 57 which enables this bag to be closed and reopened as desired.
- a black line 58 is provided on at least one side of the bag as a convenience in indicating the proper quantity of fluid sample to be placed in the envelope.
- a flat bag or envelope is preferred since such a shape bag has a minimum volume and requires a lesser quantity of sample for testing.
- the bag or envelope may be shaped to be curved or bulging so as not to be strictly flat but such a shape would still require a small quantity of sample when the test card is inserted in the bag.
- the bag 54 be of a transparent material since this greatly facilitates reading of the test results when the card is within the bag.
- the bag may be of a translucent or even opaque material of the type which would enable the test card to be read when the card is in close contact with the surface of the test bag.
- a fluid sample for drugs of abuse preferably 2.0 ml. of the urine specimen is introduced into the bottom of the bag 54 by a pipette 59 or any other suitable or available dispensing device such as a dropper.
- the quantity of the specimen may range from 0.5-3.0 ml., however, the optimum or preferred range is 1.5-2.0 ml.
- the fluid specimen is filled to the black line 58 and at the same time care must be taken that the corners of the flat bag are filled with fluid.
- the bag is positioned in a vertical position and is maintained in this vertical position during the duration of the test.
- a test card 44 such as illustrated in FIGS. 8 or 10 is then inserted through the top opening 55 of the bag and moved in a downward direction as indicated by the arrow 60 until the card rests completely on the bottom of the bag as shown in FIG. 17.
- the bag is preferably, but not necessarily sealed as an added precaution against the spilling accidentally or otherwise of the specimen during the test.
- the level of the fluid sample will then rise to approximately the level indicated by the arrow 61 in FIG. 17.
- the test card and bag assembly is then maintained in a vertical position and the test results may be read in 5-10 minutes.
- the bag and card While it is preferable that the bag and card be maintained in a substantially vertical position during the test, it has been discovered that the card and bag may be positioned at 30-45° without adversely affecting the test.
- the drug test card 44 may be positioned at a 30-45 degree angle as shown in FIG. 18 to elevate the top portion of the test card.
- This figure illustrates the use of a block-like object at 62 against which the test card 44 is inclined, but it is to be understood that any object available may be sued to give the desired inclined position.
- each immunoassay test strip such as by use of a pipette indicated at 63 in FIG. 18. This procedure is repeated until approximately 200 micro liters (about 5 to 7 drops) have been added to each channel or test strip.
- a test card which has additional test strips on the reverse side
- the card is then turned over and the procedure repeated on the reverse side.
- the card is maintained at this supported angle until test results are evident which are generally in 5-10 minutes.
- any other suitable or appropriate device for dispensing the fluid specimen drop wise onto each test strip may be employed.
- the specimen is added to the sample receiving openings 51 at the bottom of the test card.
- Quality control specimens of urine are commercially available and each such specimen usually measures 2.0 ml. Such a specimen may have only one analyte therein corresponding to a particular drug or as many as eight different analytes corresponding to eight different drugs of abuse. When these control materials are used, the same procedure is followed as described above for a low volume drug abuse test.
- quality control specimens which have analyte concentrations 25% greater than the cut-off level should be used.
- quality control samples are positive in that they have therein at least one analyte corresponding to the drug or drugs to be tested.
- negative control samples may be used in which are clean in that there are no drug analytes present.
- This control sample is introduced into the bottom of the flat container through the opening at the top.
- the drug test card is then inserted through the opening at the top of the container to the bottom of the container so as to contact the fluid sample therein.
- this indication confirms that the test strip is capable of detecting that drug within an accepted range of the cut-off level.
- the concentration of the drug is at a level higher than the cut-off level of the test strip.
- Each of the test strips 26 - 30 is a one-step immunoassay in which a specially labeled drug, (drug conjugate) competes with drug which may be present in the sample for the limited number of binding sites on an antibody.
- the test strip consists of a membrane strip onto which a drug conjugate has been immobilized.
- a colloidal gold-antibody complex is dried at one end of the membrane.
- the colloidal gold-antibody complex -moves with the urine sample by capillary action to contact the immobilized drug conjugate.
- An antibody-antigen reaction occurs forming a visible line in the test area. The formation of a visible line in the test area occurs when the test is negative for the drug.
- a single test line indicates that the sample contains either no analyte or its presence is below the cut-off level.
- the drug or its metabolite will compete with the immobilized drug conjugate in the test area for the limited antibody sites on the colloidal gold-labeled antibody complex. If a sufficient amount of drug is present, it will fill all of the available binding sites, thus preventing attachment of the label antibody to the drug conjugate.
- An absence of a color line or band in the test area is indicative of a positive result.
- a control band or line comprised of a different antibody/antigen reaction is present on the membrane strip. The control line is not influenced by the presence or absence of drug in the urine and therefore should be present in all reactions.
- test card can also be used as a carrier or delivery system for a biological detection or monitor device by replacing the drug test strips with strips treated with suitable chemicals so as to be responsive to different and selected biological warfare agents.
- the strips would then function similarly to drug abuse strips to provide a visual indication of the presence in a predetermined quantity of a specific biological warfare agent or the absence of such an agent.
- the present invention discloses a novel and improved drug abuse test kit which comprises a container for the fluid specimen being tested and a multiple drug test card which is inserted in the specimen within the container and the visual results of the test are read on the test card through the wall of the container.
- the test card thus comprises a number of individual test strips of the immunoassay type and each strip is responsive or indicative to a particular drug of abuse.
- the test card may be made of plastic coated cardboard or thin sheets of plastic which are laminated together.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
- This is a continuation-in-part application of U.S. patent application Ser. No. 08/981,665 filed Nov. 5, 1997 which is a continuation-in-part of application Ser. No. 08/613,487 filed Mar. 11, 1996.
- The present invention relates to a test kit for the collection and testing of urine samples for drugs of abuse and subsequent shipment of the sample, more particularly, to such a test kit for low volumes of urine samples and having a transparent envelope-type container and a test card for indicating visually the presence of particular drugs of abuse.
- The increased availability and use of drugs of abuse by the general population has caused employers, governmental agencies, sports groups and other organizations to utilize drug screening both as a condition of employment and in order to maintain safety in the work place. Urine-based screening tests for the detection of drugs of abuse range in complexity from simple immunoassay tests to very complex analytical procedures. Over the years the speed and specificity of immunoassays have made them one of the most accepted methods for screening for drugs of abuse in urine. Typical drug screening tests are performed for the purpose of quickly identifying on a qualitative basis the presence of drugs in a body fluid which may be urine. A complete analysis of the sample may then be carried out in a laboratory only if the preliminary screening results are positive. More and more such drug screenings are taking place on site or the work place and are generally carried out by testing personnel who are generally not technically trained, such as laboratory technicians. It is thus important that the drug screening procedure is simple but yet reliable. Further, the test apparatus must be such so as to enable the testing personnel to avoid all contact with the fluid specimen which is being tested.
- Various forms of devices had been proposed for the collection and taking of body fluids, such as urine, which have proved to be cumbersome in operating since they involve a number of separate steps. Initially, the sample was collected and several additional steps were then required to transfer the urine sample to an analysis device. This multiple step procedure required the manual handling of the specimen through various devices and the use of such transfer devices inevitably caused spills which may result in contamination to the tester and surroundings. In addition, nontechnical personnel who perform the screening tests on urine samples objected to coming into any kind of contact with the urine sample and even the handling of the sample itself.
- Many of the known testing devices were rather complex in that they included a container for the specimen, and, subsequently it was necessary to transfer the specimen or at least a portion thereof to another compartment of the container in order to perform the test. This transfer of the specimen required vigorous shaking of the container or turning the container upside down in order to cause the flow of the specimen into a test compartment. It was therefore necessary to make the containers leak proof under such condition and the result was a complicated and expensive container structure.
- Further, the containers incorporated the structure by means of which reagent strips were mounted in a test compartment of the container and which structure also enabled the fluid sample to flow into the test compartment into contact with the reagent strips. Such a mounting of the reagent strips further resulted in complicating the structure of the container since it was also necessary that provision be made to view the reagent strips from outside of the container. This was generally achieved by providing a transparent window or some other mounting of the reagent strips so that they are visible to testing personnel.
- Generally, cylindrical or cup-like containers, usually made of a thermoplastic material, are used. However, the volume of such containers requires a urine sample of the order of 15 ml. which under some circumstances may not be available. In the drug testing of infants or persons who are admitted under emergency conditions to a hospital or clinic, only a bare minimum of a urine sample may be available and this bare minimum would not be sufficient to conduct a drug abuse test with the usual cup-like container. For the drug testing of such persons, for infants, resort may be had to wringing the diapers to obtain a few drops of urine therefrom and even in the case of seriously injured persons, a few drops of a urine sample might be available from the clothing.
- It is therefore the principal object of the present invention to provide a simplified and inexpensive device for the collection and testing of low volumes of body fluid samples, particularly urine, for drugs of abuse and subsequent shipment of the sample.
- It is an additional object of the present invention to provide a drug test kit which includes a flat envelope or bag container for retaining a urine sample having such a closure structure that when a test card having a plurality of test strips is introduced into the container, the test strips will contact the urine sample.
- It is a further object of the present invention to provide a test card having a plurality of immunoassay test strips thereon with each strip being responsive to a particular drug of abuse and having a visual endpoint to indicate the presence or absence of a particular drug.
- It is another object of the present invention to provide a novel and improved process for the testing of low volumes of a fluid sample for drugs of abuse using a test card having a plurality of immunoassay test strips thereon.
- The objects of the present invention are achieved and the disadvantages of the prior art are eliminated by the drug abuse test device according to the present invention which may comprise a flat envelope or bag transparent container for retaining a urine sample to be tested. The open top of the container is of such a size to accommodate a test card which has a plurality of immunoassay test strips mounted thereon in parallel on one or both sides and each test strip is responsive to a particular drug of abuse. The test card is insertable through the open top or end so as to have one end immersed in the urine sample to a predetermined depth whereby the visual results of each test strip can be seen through the transparent or translucent wall of the container without removing the test card from the container so as to indicate the presence or absence of a particular drug of abuse in the urine sample. If the sample should test “positive” to indicate the presence of a drug in the urine, it is then necessary to send the sample to a certified laboratory for confirmatory testing.
- As described above, the test kit includes a drug abuse test device for collecting and testing a urine sample. This test device comprises a flat envelope or bag preferably having a transparent wall and having an open top or end in the shape of a slit therein to receive a test card.
- This new test kit would thus test as little as 2.0 ml. of urine or any other fluid sample as compared with the usual 30-48 ml. such as when a test cup is used. This test kit incorporates a particular structure of a container rather than the usual test cup. This ability to test lower volumes is ideal for use in hospital and clinical settings as well for compliance with laboratory certification and quality control requirements.
- The test kit also includes a test card for drugs of abuse which may comprise a thin flat member having the size and shape of a business card. A plurality of immunoassay test strips are fastened side by side in parallel on one side of the test card within the outline of the card. Each test strip is reactive to provide a visual indication in response to a particular drug of abuse. This test card thus provides for the simultaneous detection of multiple analytes.
- Other objects and advantages of the present invention will be apparent upon reference to the accompanying description when taken in conjunction with the following drawings, which are exemplary, wherein;
- FIG. 1 is a perspective view of the drug abuse test kit according to the present invention generally showing the container, the test card partially inserted to the testing position in the container through a slit in the cover;
- FIG. 2 is an exploded perspective view of the container according to the present invention for collecting and testing a fluid sample and generally showing the container, a cover having a slit covered with a removable adhesive seal and a second solid closure cap;
- FIG. 3 is a plan view of the test side of a test card according to the present invention;
- FIG. 4 is a plan view of the reverse side of the test card shown in FIG. 3;
- FIG. 5 is an end elevational view of the test card shown in FIG. 3;
- FIG. 6 is a sectional view taken along the lines VI-VI of FIG. 3 but showing a modification wherein the test strips are flush with the top surface of the test card;
- FIG. 7 is a plan view of the opened two piece test card before it is folded over to form the test card shown in FIGS.3-6;
- FIG. 8 is a plan view of another modification of the test card;
- FIG. 9 is a sectional view taken along the lines IX-IX of FIG. 8.
- FIG. 10 is a plan view of the test side of a further modification of the test card;
- FIG. 11 is a plan view of the center ply of the test card of FIG. 10 and showing a test strip in a slot thereof;
- FIG. 12 is a plan view of the reverse side of the test card of FIG. 10;
- FIG. 13 is a sectional view taken along the lines XIII-XIII of FIG. 10.
- FIG. 14 is a plan view of a flat polybag or envelope used in the low volume test;
- FIG. 15 is a side elevational view of the envelope or bag shown in FIG. 14;
- FIG. 16 is a plan view of a polybag according to FIG. 14 with a drug test card partially inserted therein;
- FIG. 17 is a view similar to that of FIG. 16 but shows a drug test card inserted within the polybag in the testing position;
- FIG. 18 is a perspective view of a drug test card in an inclined position for a low volume test utilizing a pipette to dispense the sample to be tested directly onto the test card.
- As may be seen in FIGS. 1 and 2, a drug abuse test kit according to the present invention is indicated generally at10 and comprises a cup-like transparent test container or cup 11 having a
cylindrical side wall 12, a closed bottom 13 and an open top 14. Thecylindrical wall 12 may have a slight taper or be straight. - The
open end 14 of the test cup 11 is provided withexternal threads 21 upon which is seated an outer closure cover or cap 22 provided with corresponding internal threads which are not shown in the drawing. Thecover 22 has a circulartop surface 23 from the periphery of which depends acylindrical wall 24 on the inner surface of which there are provided internal threads. Thecover surface 23 has adiametrical slit 19 therein shaped to accommodate a test card as will be presently described. There may also be provided a solid cover or cap 15 positioned on the bottom of the test cup but removable and which is similar in size and shape to thecover 22 but is solid or unslit so that thecovers open end 14 of the test cup 11 if shipment of the container and sample is desired. Atemperature strip 16 is mounted on the bottom side wall of the test cup so as to be responsive to the temperature of the test sample within a test cup. - The cup container is essentially a specimen cup as commonly used in medicine and has a wall of material normally impervious to fluid specimens contained therein. The container may be formed or molded from any suitable material, such as a thermal plastic. It is preferred that the container is transparent since this enables the results from the test card to be read without removing the test card from the cup. But a transparent wall is not necessary and the wall may be translucent or even opaque. If an opaque material is used, it is preferred that the material be such that a test strip would be visible and read when the test card is close to or in contact with a wall of the container. Further, while the cup shown is cylindrical, it is to be understood that other shapes could be used.
- A
test card 25 which will indicate the presence or absence of any one of 5 different drugs of abuse is shown in FIG. 1 inserted within theslit 19 in theclosure cap 22 and in further detail in FIGS. 3-6. The test card is of the multiple drug type in that test strips for five different drugs of abuse are mounted on the test card. The test strips 26-30 are spaced apart in parallel on atest side 31 of the test card. These test strips indicate the presence or absence of the following specific drugs of abuse: PCP, cocaine, amphetamines (AMP), marijuana (THC) and opiates. Test strips 26-30 may be of the type as made by Bionike of South San Francisco, California, Phamatech of San Diego, Calif. and Arista Biological of Bethlehem, Pennsylvania. Such test strips are characterized as immunoassay strips and employ colloidal gold chemistry. Each test strip is submerged up to a maximum line indicated at 32 and the results of the test are read in a test area indicated at 33. A blue line in the test area indicates positive or the presence of the particular drug in the test sample. - The test strips may be completely recessed as shown in FIG. 6 or partially recessed in the slots in the card so that portions of the test strip may project above the
test surface 31 of the card as shown in FIG. 5. If the test strips are completely recessed, then the strips would be flush with the top surface of the top ply as shown in FIG. 6. The test card may be formed of twoplys ply 35 is formed with a plurality of die cutslots 37 which are shaped and sized to receive each of the test strips. Thus, in the fabrication of a test card, the twoportions end 36 and are adhered together. The test strips are then placed into the slots as shown in FIG. 6 and each of the test strips is adhered to the surface of thefirst portion 34 upon which thesecond portion 35 has been folded. In this modification the test strips are flush with thetest surface 31. - It is also within the scope of this invention to make this test card of two separate or
individual plys - In order to conduct a drug abuse test utilizing the test card according to the present invention a person being tested must first provide a urine specimen into the transparent test cup11. The quantity of specimen provided must be such as to permit insertion of the test card up to about the maximum line indicated at 32. It is also possible to provide fill lines on the wall surface of the test container. Usually, 30-48 ml. of specimen is sufficient.
- The test cup with a sufficient quantity of test specimen therein is then closed by threading the
cap 22 on the top of the test cup. Thecap 22 is provided with a readily removableadhesive sealing strip 18 which is placed over theslit 19. Thus, when the container with the test specimen is brought to the person conducting the test, theprotective strip 18 is removed and the multipledrug test card 25 inserted into the slit so that the bottom of the test card rests upon the bottom of the test cup. 30-48 ml. of specimen will ensure that the specimen contacts the sample receiving portions of all of the test strips. The test card then remains in place for at least three minutes. results of the test can be read on each individual test strip through the transparent wall of the container. Thus, if a blue line appears on any one of the test strips, this indicates positive and the presence of that particular drug of abuse in the test specimen. If no such blue line appears then the absence of any of the five drugs of abuse from the specimen is indicated. With such a negative result, the urine sample and the container are discarded. - However, when the results of the test are positive, it is preferable to send the specimen to a certified laboratory for a confirmatory analysis by more specific methods of testing such as gas chromatography or mass spectrometry. In order to ship the sample in the container, the
closure 22 is removed and thesolid cover 15 is threaded down tightly upon the open end of the container. - A modification of the test card is shown at44 in FIG. 8. In this modification, the test strips are covered but the pertinent test and sample portions of the test strips are exposed through openings. The
test card 44 comprises acentral ply 45 of styrene which has a thickness of 1.25 mm. corresponding to or slightly greater than the thickness of the test strips and slots are provided in the center ply to receive the test strips. The top and bottom faces of thecentral ply 45 are covered by abottom ply 46 and atop ply 47 which may be made from a single piece of material double scored at 48 and 49 so as to wrap around thecentral ply 45 in the manner as shown in FIG. 10. The top and bottom plys may be of a thin vinyl sheet or cardboard coated with plastic. The top ply 47 is provided with a plurality oftest windows 50 through which the test results as indicated by the test strips can be seen. At the lower end of the card are providedsample openings 51 through which the liquid test specimen is able to contact the absorbent or sample portions of the test strips. - In FIGS.10-13 there is shown a modification of the
test card 44 in which the card is made of three separate plys which are then laminated. The bottom andtop plys windows 50 and thesample openings 51 and the bottom ply 46 is solid as shown. - The
central ply 45 is provided with a plurality of longitudinally extendingslots 52 and atest strip 53 is seated in each of these slots as shown. The test strip generally has a length less than that of theslot 52. In this embodiment, only a single test strip for THC (marijuana) is shown. While this embodiment of the test card has provision for five test strips, it is to be understood that the card can be made in the same manner with less than five strips and even a single strip if so desired. In such a modification, thewindows - Proceeding next to FIG. 14, there is shown at54 a clear recloseable bag or envelope of polyethylene which is used in the testing of low volumes of fluid samples for drugs of abuse. The
bag 54 is a transparent flat bag or envelope having a rectangular configuration and a top 55 which is open and a bottom 56. The top 55 is provided with a zip-lock 57 which enables this bag to be closed and reopened as desired. Ablack line 58 is provided on at least one side of the bag as a convenience in indicating the proper quantity of fluid sample to be placed in the envelope. A flat bag or envelope is preferred since such a shape bag has a minimum volume and requires a lesser quantity of sample for testing. However, the bag or envelope may be shaped to be curved or bulging so as not to be strictly flat but such a shape would still require a small quantity of sample when the test card is inserted in the bag. - It is preferred that the
bag 54 be of a transparent material since this greatly facilitates reading of the test results when the card is within the bag. However, the bag may be of a translucent or even opaque material of the type which would enable the test card to be read when the card is in close contact with the surface of the test bag. - In carrying out the process for testing of low or small volumes of a fluid sample for drugs of abuse, preferably 2.0 ml. of the urine specimen is introduced into the bottom of the
bag 54 by apipette 59 or any other suitable or available dispensing device such as a dropper. The quantity of the specimen may range from 0.5-3.0 ml., however, the optimum or preferred range is 1.5-2.0 ml. The fluid specimen is filled to theblack line 58 and at the same time care must be taken that the corners of the flat bag are filled with fluid. The bag is positioned in a vertical position and is maintained in this vertical position during the duration of the test. - A
test card 44 such as illustrated in FIGS. 8 or 10 is then inserted through thetop opening 55 of the bag and moved in a downward direction as indicated by thearrow 60 until the card rests completely on the bottom of the bag as shown in FIG. 17. The bag is preferably, but not necessarily sealed as an added precaution against the spilling accidentally or otherwise of the specimen during the test. When the bottom of the card rests upon the bottom of the bag, the level of the fluid sample will then rise to approximately the level indicated by the arrow 61 in FIG. 17. The test card and bag assembly is then maintained in a vertical position and the test results may be read in 5-10 minutes. - While it is preferable that the bag and card be maintained in a substantially vertical position during the test, it has been discovered that the card and bag may be positioned at 30-45° without adversely affecting the test.
- As a modification of the above described process, the
drug test card 44 may be positioned at a 30-45 degree angle as shown in FIG. 18 to elevate the top portion of the test card. This figure illustrates the use of a block-like object at 62 against which thetest card 44 is inclined, but it is to be understood that any object available may be sued to give the desired inclined position. - The specimen is then introduced drop-wise to each immunoassay test strip such as by use of a pipette indicated at63 in FIG. 18. This procedure is repeated until approximately 200 micro liters (about 5 to 7 drops) have been added to each channel or test strip. When a test card is used which has additional test strips on the reverse side, the card is then turned over and the procedure repeated on the reverse side. The card is maintained at this supported angle until test results are evident which are generally in 5-10 minutes. It is to be understood that while the use of a pipette is illustrated in FIG. 18, any other suitable or appropriate device for dispensing the fluid specimen drop wise onto each test strip may be employed. As illustrated in FIG. 18, the specimen is added to the
sample receiving openings 51 at the bottom of the test card. - It is good laboratory practice for hospitals, clinics and other institutions or entities which administer numerous drug tests to use quality control materials to ensure proper test performance. Quality control specimens of urine are commercially available and each such specimen usually measures 2.0 ml. Such a specimen may have only one analyte therein corresponding to a particular drug or as many as eight different analytes corresponding to eight different drugs of abuse. When these control materials are used, the same procedure is followed as described above for a low volume drug abuse test. Preferably, quality control specimens which have
analyte concentrations 25% greater than the cut-off level should be used. Generally, such quality control samples are positive in that they have therein at least one analyte corresponding to the drug or drugs to be tested. However, negative control samples may be used in which are clean in that there are no drug analytes present. This control sample is introduced into the bottom of the flat container through the opening at the top. The drug test card is then inserted through the opening at the top of the container to the bottom of the container so as to contact the fluid sample therein. Should a test strip indicate the presence of a drug, this indication confirms that the test strip is capable of detecting that drug within an accepted range of the cut-off level. Essentially, the concentration of the drug is at a level higher than the cut-off level of the test strip. - Each of the test strips26-30 is a one-step immunoassay in which a specially labeled drug, (drug conjugate) competes with drug which may be present in the sample for the limited number of binding sites on an antibody. The test strip consists of a membrane strip onto which a drug conjugate has been immobilized. A colloidal gold-antibody complex is dried at one end of the membrane. In the absence of any drug in the urine sample, the colloidal gold-antibody complex -moves with the urine sample by capillary action to contact the immobilized drug conjugate. An antibody-antigen reaction occurs forming a visible line in the test area. The formation of a visible line in the test area occurs when the test is negative for the drug. Thus, a single test line indicates that the sample contains either no analyte or its presence is below the cut-off level. When a drug is present in the urine sample, the drug or its metabolite will compete with the immobilized drug conjugate in the test area for the limited antibody sites on the colloidal gold-labeled antibody complex. If a sufficient amount of drug is present, it will fill all of the available binding sites, thus preventing attachment of the label antibody to the drug conjugate. An absence of a color line or band in the test area is indicative of a positive result. A control band or line comprised of a different antibody/antigen reaction is present on the membrane strip. The control line is not influenced by the presence or absence of drug in the urine and therefore should be present in all reactions.
- In summary, if a single band appears in the control zone and no band appears in the test zone then the results are “positive” which indicates that that particular drug is present above a predetermined level which is usually around 50 ng/ml. If two color bands appear, one in the control region and the other in the test region then the test results are “negative” which indicates that the level of that particular drug is below the predetermined detection of sensitivity.
- In the event that there are no distinct color bands visible in both the test zone and the control zone or if there is a visible band in the test zone but not in the control zone, then the result is invalid and retesting of the specimen is recommended with another test card.
- The test card can also be used as a carrier or delivery system for a biological detection or monitor device by replacing the drug test strips with strips treated with suitable chemicals so as to be responsive to different and selected biological warfare agents. The strips would then function similarly to drug abuse strips to provide a visual indication of the presence in a predetermined quantity of a specific biological warfare agent or the absence of such an agent.
- INDUSTRIAL APPLICABILITY
- Thus it can be seen that the present invention discloses a novel and improved drug abuse test kit which comprises a container for the fluid specimen being tested and a multiple drug test card which is inserted in the specimen within the container and the visual results of the test are read on the test card through the wall of the container. The test card thus comprises a number of individual test strips of the immunoassay type and each strip is responsive or indicative to a particular drug of abuse. The test card may be made of plastic coated cardboard or thin sheets of plastic which are laminated together. This drug abuse test kit enables one to obtain rapidly a visual, qualitative result which is very advantageous for forensic purposes but is not limited to such purposes.
- It will be understood that this invention is susceptible to modification in order to adapt it to different usages and conditions, and accordingly, it is desired to comprehend such modifications within this invention as may fall within the scope of the appended claims.
Claims (27)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/770,312 US6406922B2 (en) | 1996-03-11 | 2001-01-29 | Device for the testing of body fluid samples |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/613,487 US5976895A (en) | 1996-03-11 | 1996-03-11 | Device for the collection, testing and shipment of body fluid samples |
US98166597A | 1997-11-05 | 1997-11-05 | |
US27510099A | 1999-03-24 | 1999-03-24 | |
US09/770,312 US6406922B2 (en) | 1996-03-11 | 2001-01-29 | Device for the testing of body fluid samples |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US27510099A Division | 1996-03-11 | 1999-03-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20010012637A1 true US20010012637A1 (en) | 2001-08-09 |
US6406922B2 US6406922B2 (en) | 2002-06-18 |
Family
ID=27402698
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/770,312 Expired - Lifetime US6406922B2 (en) | 1996-03-11 | 2001-01-29 | Device for the testing of body fluid samples |
Country Status (1)
Country | Link |
---|---|
US (1) | US6406922B2 (en) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040146429A1 (en) * | 2001-09-04 | 2004-07-29 | Guerra Francisco Javier | Apparatus and method for testing a beverage for a clandestine illicit substance |
WO2008086401A2 (en) | 2007-01-09 | 2008-07-17 | American Bio Medica Corporation | Extraction method and apparatus for high-sensitivity body fluid testing device |
US20080305548A1 (en) * | 2007-06-11 | 2008-12-11 | American Bio Medica Corporation | Method for stimulating saliva production during oral sample collection procedure |
US7520439B1 (en) * | 2002-11-07 | 2009-04-21 | American Express Travel Related Services Company, Inc. | Portable electronic devices with convenient or foldable transaction cards |
US7682801B2 (en) | 2005-03-11 | 2010-03-23 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
US7721956B2 (en) | 2003-12-10 | 2010-05-25 | American Express Travel Related Services Company, Inc. | Foldable transaction card systems |
US7879597B2 (en) | 2005-03-11 | 2011-02-01 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
US7892371B2 (en) | 2002-11-07 | 2011-02-22 | American Express Travel Related Services Company, Inc. | Foldable transaction cards and methods of making the same |
CN102590500A (en) * | 2012-01-16 | 2012-07-18 | 宁波天润生物药业有限公司 | WFR (Weil Felix Reaction) test card |
US20120208288A1 (en) * | 2010-09-21 | 2012-08-16 | Monty Scott Ban | Unitized point-of-care urine dipstick control device |
US8603835B2 (en) | 2011-02-10 | 2013-12-10 | Chembio Diagnostic Systems, Inc. | Reduced step dual path immunoassay device and method |
US20140242716A1 (en) * | 2013-02-22 | 2014-08-28 | Larry Hartselle | Specimen Cup and Method |
US9835562B2 (en) | 2014-05-05 | 2017-12-05 | Quantimetrix | Liquid holding apparatus for insertion of a test device into a test liquid |
CN107664693A (en) * | 2016-07-27 | 2018-02-06 | 杭州博拓生物科技股份有限公司 | A kind of carrier for preventing detection reagent bar mighty torrent |
US9885710B2 (en) | 2014-04-02 | 2018-02-06 | Chembio Diagnostic Systems, Inc. | Immunoassay utilizing trapping conjugate |
WO2019175677A3 (en) * | 2018-01-24 | 2019-12-12 | Test Card Ltd. | Medical test card |
US10690667B2 (en) | 2014-10-27 | 2020-06-23 | Chembio Diagnostic Systems, Inc. | Rapid screening assay for qualitative detection of multiple febrile illnesses |
US11350913B2 (en) | 2008-07-24 | 2022-06-07 | Chembio Diagnostic Systems, Inc. | Method and apparatus for collecting and preparing biological samples for testing |
US11480563B2 (en) | 2019-03-25 | 2022-10-25 | Testcard Ltd. | Medical test card |
WO2023201671A1 (en) * | 2022-04-22 | 2023-10-26 | 宁德时代新能源科技股份有限公司 | Measurement assembly and manufacturing method therefor, and measurement apparatus and measurement system |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7063234B2 (en) * | 2000-12-29 | 2006-06-20 | Csp Technologies, Inc. | Meter strip dispenser assembly |
US7087389B2 (en) * | 2001-02-09 | 2006-08-08 | Council Of Scientific & Industrial Research | Highly cost-effective analytical device for performing immunoassays with ultra high sensitivity |
US6818181B2 (en) * | 2001-03-15 | 2004-11-16 | Savyon Diagnostics Ltd. | Kit and method for detecting food allergies |
JP4642277B2 (en) * | 2001-06-21 | 2011-03-02 | 株式会社ジーシー | Saliva pretreatment tool and saliva pretreatment method |
WO2003028582A2 (en) * | 2001-09-28 | 2003-04-10 | Aspenbio, Inc. | Bovine pregnancy test |
US7560272B2 (en) | 2003-01-04 | 2009-07-14 | Inverness Medical Switzerland Gmbh | Specimen collection and assay container |
US7459314B2 (en) * | 2003-02-13 | 2008-12-02 | Inverness Medical Switzerland Gmbh | Lateral flow immunoassay controls |
US20050009203A1 (en) * | 2003-07-11 | 2005-01-13 | Wong Johnson N.S. | Multi-drug testing device and method |
JP4667389B2 (en) * | 2003-11-14 | 2011-04-13 | アレル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | Sample collection cup with integrated sample analysis system |
EP1687621B1 (en) * | 2003-11-14 | 2018-06-27 | Alere Switzerland GmbH | Sample collection cup with integrated activatable sample analysis system |
US7582262B2 (en) | 2004-06-18 | 2009-09-01 | Roche Diagnostics Operations, Inc. | Dispenser for flattened articles |
US7758815B2 (en) * | 2004-08-03 | 2010-07-20 | Hartselle R Lawrence | Specimen collection, storage, transportation and assaying device |
JP4329816B2 (en) * | 2004-09-15 | 2009-09-09 | 萬有製薬株式会社 | Sampling method, sampling device, logD measuring method and logD measuring system |
US20060246574A1 (en) * | 2005-04-29 | 2006-11-02 | Sarah Rosenstein | Dispenser for making a lateral flow device |
US20060246599A1 (en) * | 2005-04-29 | 2006-11-02 | Sarah Rosenstein | Lateral flow device |
CN100478671C (en) * | 2005-10-25 | 2009-04-15 | 艾康生物技术(杭州)有限公司 | Detector and method for liquid sampler |
CN101078715B (en) * | 2007-06-28 | 2010-12-08 | 艾博生物医药(杭州)有限公司 | Standard solution and its formulation method and uses |
US8747117B2 (en) | 2010-09-13 | 2014-06-10 | Ekg Concepts, Llc | Rapid visual cuing apparatus for cardiac EKG rhythms |
PT2612707E (en) | 2012-01-05 | 2014-09-17 | American Bio Medica Corp | Device and method for testing biological samples |
US9005991B2 (en) | 2012-01-05 | 2015-04-14 | American Bio Medica Corporation | Device and method for testing biological samples |
USD755978S1 (en) | 2014-05-15 | 2016-05-10 | Ekg Concepts, Llc | EKG viewing tool |
USD792976S1 (en) | 2014-05-15 | 2017-07-25 | Ekg Concepts, Llc | EKG viewing tool |
USD770636S1 (en) * | 2014-09-17 | 2016-11-01 | Assure Tech.(Hangzhou) Co., Ltd. | Detection device for medical purposes |
USD836209S1 (en) * | 2015-01-16 | 2018-12-18 | Assure Tech. (Hangzhou) Co., Ltd. | Detection device for medical purposes |
JP7273727B2 (en) * | 2017-05-02 | 2023-05-15 | アイデックス ラボラトリーズ インコーポレイテッド | Sealed lateral flow device |
USD1032015S1 (en) * | 2019-04-17 | 2024-06-18 | Hangzhou Biotest Biotech Co., Ltd. | Test device |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3915806A (en) * | 1974-01-17 | 1975-10-28 | Denver Chemical Manufacturing | Specimen holding kit |
US4361537A (en) * | 1979-01-12 | 1982-11-30 | Thyroid Diagnostics, Inc. | Test device and method for its use |
US4518565A (en) * | 1983-06-06 | 1985-05-21 | Miles Laboratories, Inc. | Reagent test device holder |
DE3416933A1 (en) * | 1984-05-04 | 1985-11-07 | Dora 1000 Berlin Köhler | CARRIER COVERED WITH ANTIQUE OR ANTIBODY |
US5013667A (en) * | 1987-06-08 | 1991-05-07 | Dexsil Corporation | Apparatus and method for measuring halogen content |
US5380492A (en) * | 1990-12-18 | 1995-01-10 | Seymour; Eugene H. | Sampling device and sample adequacy system |
US5119830A (en) * | 1991-04-03 | 1992-06-09 | Code Blue Medical Corporation | Analytical specimen cup with testing means |
US5316732A (en) * | 1992-07-01 | 1994-05-31 | Smithkline Diagnostics, Inc. | Extraction vial |
US5352410A (en) * | 1993-06-03 | 1994-10-04 | Hansen Warren D | Fluid specimen collection and testing apparatus |
US5403551A (en) * | 1993-09-16 | 1995-04-04 | Roche Diagnostic Systems, Inc. | Assaying device and container for in field analysis of a specimen and later shipment of the unadulterated specimen |
IL112842A (en) * | 1995-03-02 | 1998-06-15 | Batec Bio Analytical Techn Ltd | Device for detecting microorganisms in a sample |
JP2901521B2 (en) * | 1995-07-31 | 1999-06-07 | アロカ株式会社 | Biological tissue processing equipment |
US5976895A (en) * | 1996-03-11 | 1999-11-02 | American Biomedica Corporation | Device for the collection, testing and shipment of body fluid samples |
US6231815B1 (en) * | 1996-12-03 | 2001-05-15 | Roche Diagnostics Gmbh | Storage and transport system for sample material |
US5916815A (en) * | 1997-02-14 | 1999-06-29 | National Medical Review Office Inc. | Assaying system for illicit substances using intentional false positives to initially preserve anonymity |
USD423110S (en) * | 1998-04-28 | 2000-04-18 | American BioMedica Corp. | Drug test card for drugs of abuse |
US6235010B1 (en) * | 1999-08-06 | 2001-05-22 | Becton Dickinson And Company | Closed system specimen collection container |
-
2001
- 2001-01-29 US US09/770,312 patent/US6406922B2/en not_active Expired - Lifetime
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040146429A1 (en) * | 2001-09-04 | 2004-07-29 | Guerra Francisco Javier | Apparatus and method for testing a beverage for a clandestine illicit substance |
US7892371B2 (en) | 2002-11-07 | 2011-02-22 | American Express Travel Related Services Company, Inc. | Foldable transaction cards and methods of making the same |
US7520439B1 (en) * | 2002-11-07 | 2009-04-21 | American Express Travel Related Services Company, Inc. | Portable electronic devices with convenient or foldable transaction cards |
US7721956B2 (en) | 2003-12-10 | 2010-05-25 | American Express Travel Related Services Company, Inc. | Foldable transaction card systems |
US8877450B2 (en) | 2005-03-11 | 2014-11-04 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
US8507259B2 (en) | 2005-03-11 | 2013-08-13 | Chembio Diagnostics Systems, Inc. | Dual path immunoassay device |
US7879597B2 (en) | 2005-03-11 | 2011-02-01 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
US7682801B2 (en) | 2005-03-11 | 2010-03-23 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
US9784734B2 (en) | 2005-03-11 | 2017-10-10 | Chembio Diagnostic Systems, Inc. | Dual path immunoassay device |
WO2008086401A2 (en) | 2007-01-09 | 2008-07-17 | American Bio Medica Corporation | Extraction method and apparatus for high-sensitivity body fluid testing device |
US8287809B2 (en) | 2007-06-11 | 2012-10-16 | American Bio Medica Corporation | Method for stimulating saliva production during oral sample collection procedure |
US20080305548A1 (en) * | 2007-06-11 | 2008-12-11 | American Bio Medica Corporation | Method for stimulating saliva production during oral sample collection procedure |
US11350913B2 (en) | 2008-07-24 | 2022-06-07 | Chembio Diagnostic Systems, Inc. | Method and apparatus for collecting and preparing biological samples for testing |
US20120208288A1 (en) * | 2010-09-21 | 2012-08-16 | Monty Scott Ban | Unitized point-of-care urine dipstick control device |
US8603835B2 (en) | 2011-02-10 | 2013-12-10 | Chembio Diagnostic Systems, Inc. | Reduced step dual path immunoassay device and method |
CN102590500A (en) * | 2012-01-16 | 2012-07-18 | 宁波天润生物药业有限公司 | WFR (Weil Felix Reaction) test card |
US20140242716A1 (en) * | 2013-02-22 | 2014-08-28 | Larry Hartselle | Specimen Cup and Method |
US9949724B2 (en) * | 2013-02-22 | 2018-04-24 | Instant Tech Subsidiary Acquisition Inc. | Specimen cup including test card slot and method of use thereof |
US10598657B2 (en) | 2014-04-02 | 2020-03-24 | Chembio Diagnostic Systems, Inc. | Immunoassay utilizing trapping conjugate |
US9891216B2 (en) | 2014-04-02 | 2018-02-13 | Chembio Diagnostic Systems, Inc. | Immunoassay methods utilizing trapping conjugate |
US9885710B2 (en) | 2014-04-02 | 2018-02-06 | Chembio Diagnostic Systems, Inc. | Immunoassay utilizing trapping conjugate |
US10473655B2 (en) | 2014-04-02 | 2019-11-12 | Chembio Diagnostic Systems, Inc. | Immunoassay utilizing trapping conjugate |
US10908158B2 (en) | 2014-04-02 | 2021-02-02 | Chembio Diagnostic Systems, Inc. | Immunoassay methods utilizing trapping conjugate |
US10976315B2 (en) | 2014-04-02 | 2021-04-13 | Chembio Diagnostic Systems, Inc. | Immunoassay utilizing trapping conjugate |
US9835562B2 (en) | 2014-05-05 | 2017-12-05 | Quantimetrix | Liquid holding apparatus for insertion of a test device into a test liquid |
US10690667B2 (en) | 2014-10-27 | 2020-06-23 | Chembio Diagnostic Systems, Inc. | Rapid screening assay for qualitative detection of multiple febrile illnesses |
CN107664693A (en) * | 2016-07-27 | 2018-02-06 | 杭州博拓生物科技股份有限公司 | A kind of carrier for preventing detection reagent bar mighty torrent |
WO2019175677A3 (en) * | 2018-01-24 | 2019-12-12 | Test Card Ltd. | Medical test card |
US11480563B2 (en) | 2019-03-25 | 2022-10-25 | Testcard Ltd. | Medical test card |
WO2023201671A1 (en) * | 2022-04-22 | 2023-10-26 | 宁德时代新能源科技股份有限公司 | Measurement assembly and manufacturing method therefor, and measurement apparatus and measurement system |
Also Published As
Publication number | Publication date |
---|---|
US6406922B2 (en) | 2002-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6406922B2 (en) | Device for the testing of body fluid samples | |
CA2219529C (en) | Device for the collection, testing and shipment of body fluid samples | |
US6372515B1 (en) | Device for the testing of fluid samples and process for making the device | |
US6403383B1 (en) | Diagnostic test kit for immunological assays of fluid samples | |
AU764945B2 (en) | Multiple analyte assay device with sample integrity monitoring system | |
US8206661B2 (en) | Assay device and process for the testing of fluid samples | |
US7347972B1 (en) | Multiple analyte assay device | |
WO2000063697A9 (en) | Device for the testing of fluid samples and process for making the device | |
US5817522A (en) | Self-contained assay device and method | |
US20020031845A1 (en) | Device for the collection, testing and shipment of body fluid samples | |
US8623291B2 (en) | Multiple analyte assay device | |
US20030232451A1 (en) | Device for the testing of fluid samples and process for making the device | |
GB2339616A (en) | Drug testing and sample transporting device | |
AU6301799A (en) | Device for the testing of body fluid samples | |
AU2003262462B2 (en) | Multiple analyte assay device | |
MXPA01000051A (en) | Device for the testing of fluid samples and process for making the device | |
MXPA97008669A (en) | Device for the collection, testing and shipment of body fluid samples |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 4 |
|
SULP | Surcharge for late payment | ||
AS | Assignment |
Owner name: ROSENTHAL & ROSENTHAL, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:AMERICAN BIO MEDICA CORPORATION;REEL/FRAME:022951/0625 Effective date: 20090629 Owner name: ROSENTHAL & ROSENTHAL,NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:AMERICAN BIO MEDICA CORPORATION;REEL/FRAME:022951/0625 Effective date: 20090629 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
REMI | Maintenance fee reminder mailed | ||
FPAY | Fee payment |
Year of fee payment: 12 |
|
SULP | Surcharge for late payment |
Year of fee payment: 11 |
|
AS | Assignment |
Owner name: HEALGEN SCIENTIFIC, LLC, TEXAS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:AMERICAN BIO MEDICA CORPORATION;REEL/FRAME:063403/0243 Effective date: 20230405 |